Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dr. Reddy's Laboratories Ltd Common Stock (NY:RDY)

11.78 +0.02 (+0.13%)
Streaming Delayed Price Updated: 1:33 PM EDT, Jul 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dr. Reddy's Laboratories Ltd Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Expanding the Preventive Care Frontier: Dr. Reddy’s Launches Sanofi’s Beyfortus® in India
Via AB Newswire
Topics Death
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate in Pharmaceuticals ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong historical growth, reasonable valuation, and solid financial health, making it a candidate for GARP investors. 
Via Chartmill
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) fits the GARP mold with strong historical growth, a low PEG ratio, and robust financials, making it a candidate for long-term investors. 
Via Chartmill
News headline image
Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug ↗
Alvotech and Dr. Reddy's will co-develop a biosimilar to Keytruda, aiming to expand global access to cancer treatment alternatives. 
Via Benzinga
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)
From Alvotech
Via GlobeNewswire
News headline image
DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - A GARP Candidate Worth Considering ↗
DR. REDDY'S LABORATORIES (NYSE:RDY) offers strong earnings growth, low debt, and solid profitability, making it a candidate for GARP investors. Read why it fits the Peter Lynch strategy. 
Via Chartmill
News headline image
Dr. Reddy’s Q4 & Full Year FY25 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
How does DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) stack up against Peter Lynch’s investment principles? ↗
Peter Lynch’s approach focused on identifying undervalued growth stocks with simple, scalable businesses. We examine whether DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) fits the characteristics of a... 
Via Chartmill
News headline image
Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗
Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs. 
Via Benzinga
Topics Government Supply Chain World Trade
News headline image
Would Peter Lynch consider DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) a winning stock? ↗
Let’s dive into DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) using Peter Lynch’s key investing principles, from earnings growth and debt levels to long-term scalability and valuation. 
Via Chartmill
News headline image
Alvotech and Dr. Reddy’s Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Alvotech and Dr. Reddy’s Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
News headline image
Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr Reddy's Laboratories Q3 Earnings: Double-Digit Growth Aided By Newly Acquired Nicotine Replacement Business ↗
Dr. Reddy's Q3 FY2025 revenue reached $977 million, up 16%, with $165M net income. Growth fueled by NRT portfolio and global generics expansion. 
Via Benzinga
News headline image
Dr. Reddy’s Q3 & 9MFY25 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Earnings Scheduled For January 23, 2025 ↗
 
Via Benzinga
News headline image
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices ↗
CVS' Aetna sues drug manufacturers for price-fixing and market allocation scheme. The subsidiary seeks damages and injunctions. 
Via Benzinga
Topics Lawsuit
News headline image
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio? ↗
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
News headline image
Dr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US Market
From Dr. Reddy's Laboratories, Inc.
Via Business Wire
News headline image
Dr. Reddy's Lab Delivers 'Another Good Quarter,' CEO Says As Revenue Jumps 17% ↗
Dr. Reddy's Q2 2025 report shows a revenue boost to $957 million, fueled by global generics. North American sales rose 17% year-over-year. 
Via Benzinga
News headline image
Dr. Reddy’s Q2 & H1FY25 Financial Results
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive Year
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy’s Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness Month
From Dr. Reddy’s Laboratories Inc.
Via Business Wire
Market Alert: Dr. Reddy’s Labs Reports New Data for Aurigene CAR-T Phase 1, Gets Approvals for Phase 2 Trials Progression
Via AB Newswire
News headline image
Aurigene Oncology Limited Announces Promising Results of Phase 1 Study for India’s First Trial for Novel Autologous CAR-T Cell Therapy for Multiple Myeloma
From Aurigene Oncology Limited
Via Business Wire
News headline image
Dr. Reddy’s signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
From Dr. Reddy’s Laboratories Ltd.
Via Business Wire
News headline image
Dr. Reddy's Laboratories – Elliott Wave Technical Analysis ↗
Dr Reddy's Laboratories is progressing lower within a counter trend zigzag to terminate Minor Wave 4 Grey around 5600 levels. 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.